Angle Plc. Dual testing of DNA from CTCs and ctDNA **is the key**5 Jun 2024 13:41
As far as I am concerned. It seems to me this method is vital for companies doing cancer drug trials. The trials cost £ millions, and only happen once over 4 phases. It is vital **ALL** the available information is collected. Angle have demonstrated clinically relevant DNA variants were identified in CTCs that were not present in CtDna from the same blood sample. In my opinion this now must be measured during cancer drug trials. To not track the changes to the CTC’s (as well as CtDna) before, during and after a cancer drug trial would be criminal as far as I am concerned.
Development of molecular solutions. From the RNS:-
“ANGLE has developed a research use sample-to-answer solution for dual sequencing of DNA from CTCs and CtDna from a single patient blood sample. This method enables parallel DNA profiling of CTCs and CtDna for comprehensive molecular analysis utilising third-party downstream technologies. Originally thought to be competing analytes, CTCs and CtDna are now known to provide additional and complementary information which has the potential to expand clinically actionable information, for personalised therapy, when the two are analysed together.
In ANGLE's study of 47 samples from breast, lung, ovarian and prostate cancer patients the dual analyte assay utilised a pan-cancer panel run on a high-throughput Illumina Next Generation Sequencing ("NGS") system. This study found that clinically relevant DNA variants were identified in CTCs that were not present in CtDna from the same blood draw in 70% of breast cancer patient samples, 70% of lung cancer patient samples and 60% of ovarian cancer patient samples, highlighting the potential benefit of CTC-DNA analysis alongside CtDna analysis.”.
------------------------------------------
Sitting on a gold mine in my opinion.
All IMHO.
Sign In
Follow the stocks
